FINANCIAL RESULTS FOR THE QUARTER ENDED 31/03/2017
AUDITED FINANCIAL RESULTS, AUDITORS REPORT AND DECLARATION ATTACHED21-06-2017
21-06-2017
Fixes Book Closure for Dividend & AGM
Jagsonpal Pharmaceuticals Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 26, 2017 to September 29, 2017 (both days inclusive) for the purpose of Payment of Dividend & 38th Annual General Meeting (AGM) of the Company to be held on September 29, 2017.30-05-2017
Board recommends Dividend
Jagsonpal Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 28, 2017, inter alia, has recommended a dividend at the rate of Rs. 0.10 per equity share of Rs.5/- each.28-05-2017
Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajpal Singh Kochhar21-04-2017
Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a) (i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aresko Progressive Pvt Ltd.20-04-2017
Shareholding for the Period Ended March 31, 2017
Jagsonpal Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here17-04-2017
CERTIFICATE UNDER REGULATION 40(9) OF LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS 2015.
FOR THE HALF YEAR ENDED ON 31st MARCH, 2017 I have examined all Share Transfer Deeds, Memorandum of Transfers, sub-division, consolidation, renewal, exchange or endorsement of calls/ allotment monies, Registers, files and other documents relating to JAGSONPAL PHARMACEUTICALS LIMITED maintained by MCS LIMITED pertaining to transfer of equity shares of the company for the period from 01st October, 2016 to 31st March, 2017...14-04-2017
Statement Of Investor Complaints For The Quarter Ended 31.03.2017 Under Reg 13(3)
CIN : L74899DL1978PLC009181 The National Sto Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051. BSE Limited Corporate Relationship Department Pherojbhoy Jeejeebhoy Tower Ist Floor, Dalal Street, Mumbai - 400 001. REF: JAGSONPAL PHARMACEUTICALS LIMITED SCRIPT CODE : JAGSNPHARM & 507789 SUB: STATEMENT OF INVESTOR COMPLAINTS FOR THE QUARTER ENDED 31.03.2017 Sir/Madam, Pursuant to the provision of Regulation...14-04-2017
COMPLIANCE RELATING TO THE PERIOD ENDED 31.03.2017
PLEASE FIND ENCLOSED HEREWITH COMPLIANCE CERTIFICATE UNDER REGULATION 7 OF SEBI (LODR)REGULATIONS 2015. THE COMPLIANCE RELATES FROM 01.10.2016 TO 31.03.2016 YOU ARE REQUESTED TO TAKE NOTE ON RECORD THANKING YOU FOR JAGSONPAL PHARMACEUTICALS LIMITED R K KAPOOR COMPANY SECRETARY07-04-2017